GO:0140032 glycosylation-dependent protein binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140032 glycosylation-dependent protein binding is a molecular function defined as binding to a protein upon glycosylation of the target protein.
• This binding mode is critical for immune checkpoint recognition, viral entry, antibody effector function, and cell-cell communication [1,3,4,5].
• Key proteins involved include PD-1, SARS-CoV-2 spike, staphylococcal protein A, tetraspanins CD37/CD53, perlecan, and avian coronavirus attachment protein [1,3,4,5,6,7].
• Glycosylation acts as a structural switch that creates or masks binding interfaces, as shown for PD-1 N58-glycosylation and cemiplimab binding.
• Dysregulation of glycosylation-dependent interactions contributes to cancer immune evasion, atherosclerosis, and infectious disease pathogenesis [1,4,6].
• CRISPR knockout, point mutation, and knock-in models are essential to dissect the causal role of specific glycosylation sites in these interactions.
Description
Glycosylation-dependent protein binding (GO:0140032) is a molecular function that describes the selective binding of a protein partner to a target protein only when that target carries a specific glycosylation modification [1,2]. This term captures a fundamental mechanism in biology where glycans act as recognition determinants rather than mere decorations, enabling precise control of protein-protein interactions in immunity, infection, and development [3,4,5]. The QuickGO definition states: binding to a protein upon glycosylation of the target protein. This function is distinct from lectin activity because the binding is directed toward the glycosylated protein as a whole, not merely toward the glycan moiety itself. Researchers study GO:0140032 to understand how post-translational modifications create conditional interaction surfaces that can be exploited or disrupted in disease [1,6]. For example, the PD-1 N58-glycosylation-dependent binding of monoclonal antibody cemiplimab demonstrates how a single glycosylation site can dictate therapeutic efficacy. Similarly, multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins highlights the role of glycans in viral entry. These examples underscore why GO:0140032 is a high-priority annotation for both basic and translational research.
glycosylation-dependent protein binding At A Glance
| GO ID | GO:0140032 |
|---|---|
| GO term | glycosylation-dependent protein binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a protein upon glycosylation of the target protein |
| Definition source | QuickGO |
| Related processes | Immune checkpoint regulation, viral entry, antibody effector function, cell adhesion |
| Example proteins | PD-1, SARS-CoV-2 spike, staphylococcal protein A, CD37, CD53, perlecan, avian coronavirus attachment protein |
What Is GO:0140032?
In our own words, GO:0140032 describes a binding event where a protein interacts with another protein specifically because that target protein has been glycosylated. The glycosylation modification is required for the interaction to occur; without it, binding is lost or severely reduced. This function is annotated at the molecular level and is often studied in the context of immune receptors, viral attachment proteins, and extracellular matrix components [1,3,6].
Why Is glycosylation-dependent protein binding Important in Cell Biology?
Glycosylation-dependent protein binding is important because it provides a reversible and highly specific mechanism for controlling protein-protein interactions in health and disease. Many pathogens exploit this function to gain entry into host cells, as seen with SARS-CoV-2 spike and avian coronavirus attachment protein [3,7]. In cancer, glycosylation-dependent binding of therapeutic antibodies such as cemiplimab to PD-1 can determine treatment response. In cardiovascular disease, the glycosylation-dependent interaction of perlecan core protein with LDL contributes to atherosclerosis. Understanding this function at the molecular level is therefore essential for designing glycosylation-aware biologics, vaccines, and small-molecule inhibitors.
• Enables immune checkpoint blockade by antibodies like cemiplimab through PD-1 N58-glycosylation-dependent binding.
• Facilitates viral entry for SARS-CoV-2 and avian coronavirus by glycosylation-dependent receptor binding [3,7].
• Mediates antibody effector functions such as opsonophagocytic activity of staphylococcal protein A antibodies.
• Regulates immune-specific tetraspanins CD37 and CD53 in membrane organization.
• Contributes to atherosclerosis via perlecan-LDL interactions.
• Provides a mechanism for glycosylation-dependent structural and functional properties of antibodies.
• Offers targets for therapeutic intervention in infectious disease and cancer [1,3].
• Requires advanced proteomic methods such as thermal proteome profiling for discovery.
• Informs the design of glycosylation-engineered biologics with improved efficacy.
• Highlights the need for site-specific glycosylation analysis in drug development.
Molecular Mechanism of glycosylation-dependent protein binding
Glycan recognition and target engagement
In simple terms: The binding protein recognizes a specific sugar tag on the target protein, like a key fitting a lock.
The first step in glycosylation-dependent protein binding is the recognition of a glycosylated epitope on the target protein. This often involves the binding protein interacting with both the glycan and the underlying polypeptide surface, as shown for the PD-1 N58-glycosylation-dependent binding of cemiplimab. The glycosylation must be present for binding to occur; deglycosylation abolishes the interaction. In some cases, multimerization of the binding protein is also required, as seen for SARS-CoV-2 spike proteins.
Conformational changes and binding interface formation
In simple terms: The sugar tag can change the shape of the target protein so that the binding partner can attach.
Glycosylation can induce conformational changes in the target protein that create or expose a binding interface. For example, N-glycosylation of CD37 and CD53 regulates their interactions in immune cells. Similarly, glycosylation of the viral attachment protein of avian coronavirus is essential for host cell and receptor binding. These structural rearrangements are often site-specific and can be studied using thermal proteome profiling to discover glycosylation-dependent protein function.
Cofactors and multimerization requirements
In simple terms: Sometimes the binding protein needs to pair up with itself or with other molecules to bind effectively.
Multimerization of the binding protein can be a prerequisite for glycosylation-dependent binding. Bouwman et al. showed that multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins is critical for viral entry. In the case of staphylococcal protein A antibodies, glycosylation-dependent opsonophagocytic activity requires specific antibody glycoforms. These cofactor requirements add layers of regulation to the binding event.
Functional consequences of binding
In simple terms: Once binding happens, it triggers a specific biological effect, like immune activation or viral entry.
The functional outcomes of glycosylation-dependent protein binding are diverse. In immune checkpoint therapy, cemiplimab binding to glycosylated PD-1 blocks inhibitory signaling. In viral infection, glycosylation-dependent binding of SARS-CoV-2 spike to receptors enables host cell entry. In atherosclerosis, perlecan core protein binding to LDL promotes lipid retention. Antibody glycosylation can also modulate effector functions such as opsonophagocytosis [4,8]. These downstream effects make GO:0140032 a key node in disease pathways.
Regulation by glycosylation enzymes
In simple terms: Enzymes that add or remove sugars control whether this binding can happen.
The presence or absence of glycosylation is regulated by glycosyltransferases and glycosidases. For example, the N-glycosylation status of PD-1 is controlled by cellular glycosylation machinery, and this directly affects cemiplimab binding. Similarly, glycosylation of CD37 and CD53 is dynamically regulated in immune cells. Thermal proteome profiling has been used to discover how glycosylation-dependent protein function is regulated globally. Understanding this regulation is essential for manipulating GO:0140032 in therapeutic settings.
Key Genes Involved in GO:0140032 glycosylation-dependent protein binding
The following genes and proteins are central to glycosylation-dependent protein binding (GO:0140032), based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDCD1 | Immune checkpoint receptor; N58-glycosylation required for cemiplimab binding | Cancer immunotherapy target |
| S | SARS-CoV-2 spike protein; multimerization- and glycosylation-dependent receptor binding | Viral entry and vaccine design |
| SPA | Staphylococcal protein A; glycosylation-dependent antibody binding | Antibody effector function |
| CD37 | Tetraspanin; N-glycosylation-dependent regulation in immune cells | Immune cell signaling |
| CD53 | Tetraspanin; N-glycosylation-dependent regulation in immune cells | Immune cell signaling |
| HSPG2 | Perlecan core protein; glycosylation-dependent interaction with LDL | Atherosclerosis |
| S1 | Avian coronavirus attachment protein; glycosylation essential for receptor binding | Host-pathogen interaction |
| IgG | Antibody; glycosylation-dependent structural and functional properties | Therapeutic antibody development |
| FcR | Fc receptor; binds glycosylated antibodies | Opsonophagocytosis |
| LDLR | LDL receptor; interacts with perlecan-LDL complexes | Lipid metabolism |
| ACE2 | SARS-CoV-2 receptor; binds glycosylated spike | Viral entry |
| DPP4 | Avian coronavirus receptor; binds glycosylated attachment protein | Viral entry |
| CD4 | T cell co-receptor; glycosylation-dependent interactions | Immune regulation |
| CD8 | T cell co-receptor; glycosylation-dependent interactions | Immune regulation |
| ITGB1 | Integrin; glycosylation-dependent binding to extracellular matrix | Cell adhesion |
| EGFR | Growth factor receptor; glycosylation-dependent ligand binding | Cancer signaling |
| MUC1 | Mucin; glycosylation-dependent interactions | Cancer biomarker |
How Is glycosylation-dependent protein binding Regulated?
Glycosylation-dependent protein binding is regulated at multiple levels. The expression and activity of glycosyltransferases and glycosidases determine the glycosylation status of target proteins, thereby controlling whether binding can occur [1,5]. Cellular metabolic state can influence glycosylation patterns, as seen in immune cells and cancer cells. Multimerization of binding partners can also regulate the interaction, as demonstrated for SARS-CoV-2 spike proteins. Additionally, antibody glycosylation profiles can be modulated during immune responses, affecting effector functions [4,8]. Thermal proteome profiling has emerged as a powerful method to discover global regulators of glycosylation-dependent protein function.
glycosylation-dependent protein binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDCD1 | Cancer immunotherapy response | PD-1 knockout and N58 point mutant cell lines |
| S | COVID-19 viral entry | SARS-CoV-2 spike glycosylation mutants in ACE2-expressing cells |
| HSPG2 | Atherosclerosis | Perlecan knockout mice and LDL binding assays |
| CD37 | Immune cell signaling | CD37 knockout and glycosylation-site mutants |
| SPA | Staphylococcal infection | Protein A antibody glycosylation variants in opsonophagocytosis assays |
Cancer immunotherapy and immune evasion
Glycosylation-dependent protein binding plays a critical role in cancer immunotherapy. The PD-1 N58-glycosylation-dependent binding of cemiplimab is essential for immune checkpoint blockade, and alterations in PD-1 glycosylation can affect therapeutic response. Tumor cells often exploit glycosylation to evade immune detection, making this function a target for drug development. Understanding the glycosylation status of immune checkpoints can guide patient stratification and combination therapies.
Viral infections and host cell entry
Many viruses depend on glycosylation-dependent protein binding for host cell entry. SARS-CoV-2 spike protein requires multimerization and glycosylation for receptor binding, which is a key step in infection. Avian coronavirus attachment protein glycosylation is essential for host cell and receptor binding. These interactions are potential targets for antiviral drugs and vaccines that disrupt glycosylation-dependent binding [3,7].
Cardiovascular disease and atherosclerosis
The glycosylation-dependent interaction of perlecan core protein with LDL contributes to atherosclerosis by promoting lipid retention in the arterial wall. This binding event is a potential therapeutic target for cardiovascular disease. Modulating glycosylation of perlecan or LDL could reduce atherosclerotic plaque formation.
Antibody effector functions and infectious disease
Glycosylation-dependent opsonophagocytic activity of staphylococcal protein A antibodies highlights the importance of antibody glycosylation in fighting bacterial infections. Antibody glycosylation also affects structural and functional properties, influencing therapeutic efficacy. These findings have implications for vaccine design and monoclonal antibody engineering [4,8].
From glycosylation-dependent protein binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does glycosylation at a specific site mediate binding? | Point mutation of the glycosylation site (e.g., N58Q in PD-1) |
| Is the gene required for glycosylation-dependent binding? | CRISPR knockout of the target gene [1,5] |
| Can glycosylation-dependent binding be restored? | Knock-in of wild-type or glycosylation-deficient alleles |
| Where does the binding occur in cells? | Tagged knock-in with fluorescent protein for imaging |
| Does overexpression enhance binding? | Overexpression of the binding partner or target protein |
| What is the global impact of glycosylation on protein function? | Thermal proteome profiling in wild-type and glycosylation mutants |
How to Study the glycosylation-dependent protein binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Thermal proteome profiling | Changes in protein thermal stability upon glycosylation | Discovering glycosylation-dependent protein function |
| Mass spectrometry glycomics | Glycan composition and site occupancy | Antibody glycosylation analysis |
| Surface plasmon resonance | Binding affinity and kinetics | PD-1-cemiplimab interaction |
| Pseudovirus entry assay | Viral entry efficiency | SARS-CoV-2 spike glycosylation mutants |
| Co-immunoprecipitation | Protein-protein interactions in cells | CD37/CD53 interactions |
| CRISPR knockout screen | Genes required for binding | Identifying glycosylation regulators |
| Opsonophagocytosis assay | Antibody effector function | Staphylococcal protein A antibodies |
| LDL binding assay | Perlecan-LDL interaction | Atherosclerosis research |
Thermal proteome profiling for discovery
Thermal proteome profiling (TPP) is a powerful mass spectrometry-based method to discover glycosylation-dependent protein function. Hevler et al. used TPP to identify proteins whose thermal stability changes upon glycosylation, revealing new insights into GO:0140032. This method can be applied to cell lysates or intact cells and is compatible with CRISPR knockout models to validate targets.
Site-specific glycosylation analysis by mass spectrometry
Integrating multiple MS techniques allows in-depth antibody glycosylation analysis, revealing glycosylation-dependent structural and functional properties. These methods can identify specific glycoforms that mediate binding to partners such as Fc receptors or PD-1 [1,8]. They are essential for characterizing therapeutic antibodies and designing glycosylation-engineered biologics.
Binding assays for glycosylation-dependent interactions
Enzyme-linked immunosorbent assays (ELISAs), surface plasmon resonance (SPR), and co-immunoprecipitation can measure glycosylation-dependent binding. For example, cemiplimab binding to PD-1 is abolished when PD-1 is deglycosylated, as shown by binding assays. Similarly, SARS-CoV-2 spike binding to ACE2 is glycosylation-dependent and can be tested using pseudovirus entry assays.
CRISPR screens for glycosylation regulators
Genome-wide CRISPR knockout screens can identify genes that regulate glycosylation-dependent protein binding. Such screens have been used to discover glycosylation enzymes and transporters that control PD-1 glycosylation and cemiplimab binding. These screens are valuable for uncovering new therapeutic targets in cancer immunotherapy.
How CRISPR Can Be Used to Study GO:0140032 glycosylation-dependent protein binding
Knockout
CRISPR knockout of genes encoding glycosyltransferases or target proteins can abolish glycosylation-dependent binding. For example, knocking out PDCD1 or its glycosylation machinery eliminates cemiplimab binding. Knockout of CD37 or CD53 reduces their glycosylation-dependent regulation in immune cells. These models are essential for establishing causality.
Point Mutation
Point mutations at specific glycosylation sites (e.g., N58Q in PD-1) can prevent glycosylation and disrupt binding. This approach precisely tests the role of individual glycosylation sites in GO:0140032. Similar point mutations in SARS-CoV-2 spike can reveal glycosylation-dependent receptor binding.
Knock-in
Knock-in of wild-type or glycosylation-deficient alleles allows rescue experiments to confirm that a specific glycosylation site is necessary and sufficient for binding. This is particularly useful for studying PD-1 N58 glycosylation and cemiplimab binding. Knock-in models can also be used to introduce tagged versions of proteins for imaging.
Overexpression
Overexpression of the binding partner or the target protein can enhance glycosylation-dependent binding and facilitate biochemical studies. For example, overexpression of SARS-CoV-2 spike in ACE2-expressing cells increases viral entry. Overexpression of perlecan core protein can increase LDL binding in atherosclerosis models.
How EDITGENE Supports glycosylation-dependent protein binding Research
Researchers studying glycosylation-dependent protein binding-related genes often need to determine whether a candidate gene is causally involved in the binding event or is merely a bystander. This requires precise genetic models that can isolate the contribution of specific glycosylation sites and protein domains. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for glycosylation-dependent protein binding research.
Frequently Asked Questions About glycosylation-dependent protein binding
What is glycosylation-dependent protein binding?
Glycosylation-dependent protein binding (GO:0140032) is a molecular function where a protein binds to a target protein only when the target is glycosylated [1,2].
What genes are involved in glycosylation-dependent protein binding?
Key genes include PDCD1, CD37, CD53, HSPG2, and viral genes such as SARS-CoV-2 S and avian coronavirus S1 [1,3,5,6,7].
How does glycosylation affect protein-protein interactions?
Glycosylation can create or mask binding interfaces, induce conformational changes, and regulate multimerization, thereby controlling interactions [1,3,5].
What diseases are associated with glycosylation-dependent protein binding?
Cancer immunotherapy response, viral infections like COVID-19, atherosclerosis, and staphylococcal infections [1,3,4,6].
What methods are used to study glycosylation-dependent protein binding?
Thermal proteome profiling, mass spectrometry, surface plasmon resonance, and CRISPR screens [1,2,8].
How can CRISPR be used to study glycosylation-dependent binding?
CRISPR knockout, point mutation, knock-in, and overexpression models can test the role of specific glycosylation sites [1,3].
What is the role of PD-1 glycosylation in cancer therapy?
N58-glycosylation of PD-1 is required for cemiplimab binding, affecting immune checkpoint blockade efficacy.
How does SARS-CoV-2 use glycosylation-dependent binding?
SARS-CoV-2 spike protein requires multimerization and glycosylation for receptor binding and host cell entry.
What is thermal proteome profiling?
A mass spectrometry method to discover glycosylation-dependent protein function by measuring thermal stability changes.
Can glycosylation-dependent binding be targeted therapeutically?
Yes, it is a target for cancer immunotherapy, antiviral drugs, and antibody engineering [1,3,4,8].
Conclusion
Glycosylation-dependent protein binding (GO:0140032) is a fundamental molecular function that governs diverse biological processes, from immune checkpoint regulation to viral entry and atherosclerosis. The interplay between glycosylation and protein-protein interactions offers numerous opportunities for therapeutic intervention. Continued research using advanced CRISPR models and proteomic methods will further illuminate this critical function.
References
- 1. Lu D et al.. 2022. PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.. Front Immunol 13:826045 PMID: 35309324
- 2. Hevler JF et al.. 2025. Discovering Glycosylation-Dependent Protein Function by Thermal Proteome Profiling.. bioRxiv PMID: 41573896
- 3. Bouwman KM et al.. 2021. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins.. PLoS Pathog 17(2):e1009282 PMID: 33556147
- 4. Chen X et al.. 2020. Glycosylation-dependent opsonophagocytic activity of staphylococcal protein A antibodies.. Proc Natl Acad Sci U S A 117(37):22992-23000 PMID: 32855300
- 5. van Deventer S et al.. 2024. N-Glycosylation-dependent regulation of immune-specific tetraspanins CD37 and CD53.. Biophys J 123(15):2301-2311 PMID: 38031400
- 6. Xu YX et al.. 2015. The glycosylation-dependent interaction of perlecan core protein with LDL: implications for atherosclerosis.. J Lipid Res 56(2):266-76 PMID: 25528754
- 7. Parsons LM et al.. 2019. Glycosylation of the viral attachment protein of avian coronavirus is essential for host cell and receptor binding.. J Biol Chem 294(19):7797-7809 PMID: 30902814
- 8. Zhou Y et al.. 2025. Integrating Multiple MS Techniques for in-Depth Antibody Glycosylation Analysis: Revealing Glycosylation-Dependent Structural and Functional Properties.. Anal Chem 97(37):20435-20443 PMID: 40935804
